Secondary outcome measures will be changes in three functional rating scales , the ALS Functional Rating Scale-Revised , The EuroQOL ( EQ-5D ) , and the Hospital Anxiety and Depression Scale.Eligible patients will have El Escorial Possible , Laboratory-supported Probable , Probable or Definite amyotrophic lateral sclerosis with disease duration between 6 months and 36 months ( inclusive ) , vital capacity 60 % of predicted within 1 month prior to randomisation and age at least18 years .
